Background: Fn14 is a therapeutic target in various diseases. Results: anti-Fn14 antibodies activate the alternative NFB pathway but not other Fn14-related activities induced by soluble or membrane-bound TWEAK. FcR-bound anti-Fn14 antibodies, however, activate the full spectrum of Fn14-associated activities.
INTRODUCTION
Tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) 2 is a member of the TNF ligand family that triggers cellular responses by binding to Fn14, an unusual small member of the TNF receptor family. TWEAK is initially expressed as a membrane-bound type II protein but gets readily processed in most cell types by furin proteases resulting in the release of soluble TWEAK (1) . In fact, cell surface expressed TWEAK has so far only be detected on monocytes, macrophages, dendritic cells and some breast cancer and hepatocellular cancer cell lines (1) (2) (3) . Stimulation of Fn14 typically results in activation of transcription factors of the NFB family but the stimulation of MAP kinases and the PI3K pathway as well as the induction of necrotic and apoptotic cell death have also been reported (1) . Fn14 has no death domain and in some models its cell deathinducing activity has been indeed delineated to the NFB-mediated induction of TNF and activation of the death receptor TNFR1 together with a concomitant depletion of TRAF2-cIAP complexes which antagonizes TNFR1-induced cell death (4) (5) (6) . Noteworthy, Fn14 differently respond to soluble and membrane-bound TWEAK. While a subset of Fn14-mediated cellular responses, e.g. activation of the alternative NFB pathway and enhancement of TNF-induced apoptosis, is efficiently triggered by both TWEAK forms, activation of the classical NFB pathway is primarily stimulated by membrane-bound TWEAK (7) . Fn14 expression has been found on most tumor cell lines of non-lymphoid origin but in vivo Fn14 expression is predominately expressed during development and in injured tissue (1, 8) . TWEAK and Fn14 regulate proliferation and differentiation of mesenchymal progenitor cells, angiogenesis, but also infiltration of immune cells, cell survival and cell death what is in line with the pleiotropic functions in tissue remodeling that have been reported for these molecules (1) .
Particularly, the TWEAK-Fn14 system has been implicated in a variety of pathophysiological situations of great clinical importance. Like its name-giving cousin TNF, it contributes to the development of autoinflammatory diseases in various experimental models including, collagen induced arthritis (9,10), myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (11-13), 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis (14, 15) and systemic lupus erythematosus (SLE)-related nephritis (16) and has also been implicated in atherosclerotic plaque progression in apolipoprotein E (ApoE) knockout mice (17, 18) . Furthermore, TWEAK and Fn14 play a role in detrimental inflammatory and fibrotic processes associated with the repair of injured tissue after liver damage, denervation, stroke and renal and cerebral ischemia (19) (20) (21) (22) (23) . In view of the tissue destruction which is inevitably associated with cancer progression, it is no surprise that high Fn14 expression is evident in most solid tumors. Notably, the high tumorrelated Fn14 expression is not only evident on "activated" cells in the microenvironment but also on the malignant cells itself. Indeed, although TWEAK is cytotoxic to some tumor cell lines, in other cases activation of Fn14 results in cell migration and survival (1, 24) . Due to their disease-associated expression and function, TWEAK and Fn14 attract considerable interest as therapeutic targets. TWEAK and Fn14 can be targeted by antibodies with high selectivity and actually TWEAK-and Fn14-specific antibodies are in first clinical trials for treatment of rheumatoid arthritis, lupus and solid tumors (http://clinicaltrials.gov/). Particularly with respect to Fn14-specific antibodies different modes of action are possible in vivo. Fn14-bound antibodies might trigger destruction of the Fn14 expressing cells, e.g. by antibodydependent cellular cytotoxicity (ADCC) but could also inhibit Fn14 activation by TWEAK or even act as Fn14 agonists. Dependent on the pathophysiological scenario, inhibition and activation of Fn14 by antibodies in turn can have beneficial but also exacerbating effects. The success of an anti-Fn14 antibody therapy might thus not only depends on the best possible knowledge concerning the role of TWEAK and Fn14 in the addressed application but also on the choice of an antibody that optimally modifies the activity of Fn14-expressing cells in this particular disease. We describe here that oligomerization with protein G and Fc receptor binding uncover a latently present high agonistic activity in a non-blocking as well as a blocking antagonistic Fn14-specific antibody. More surprisingly, we observed that both the blocking as well as the non-blocking anti-Fn14 activate selectively the alternative NFB pathway without modulation of TNFR1-induced cell death, thus eliciting an agonistic quality distinct from those of the two naturally ligands of Fn14, soluble TWEAK and membrane TWEAK.
EXPERIMENTAL PROCEDURES
Cell Lines, Antibodies and Reagents -The human colorectal adenocarcinoma cell line HT29, HT1080 human fibrosarcoma cells, SKOV-3 human ovarian adenocarcinoma cells, Kym-1 human rhabdomyosarcoma cells and HEK293 human embryonic kidney cells were maintained in RPMI1640 medium (PAA, Pasching, Germany), containing 10% fetal calf serum (FCS) (30) , WiDr human colorectal adenocarcinoma cells were cultured with minimal essential medium (MEM) (Gibco, Darmstadt, Germany) again containing 10% FCS. The recombinant Fn14-specific human IgG1 antibodies PDL192 and P4A8 (25) (26) (27) were generated using the published sequences of the variable domains of these antibodies (28, 29) and sequences encoding the constant region of human IgG1(accession number P01857) and the immunoglobulin kappa chain V-J-C segment (accession number gb|AAA59000.1). Cycloheximide (CHX) was obtained from Sigma (Deisenhofen, Germany) and the recombinant protein G was from Calbiochem (San Diego, CA, USA). pCMV-SPORT6 expression vectors encoding Fc receptors were purchased from Source Bioscience (Nottigham, UK). Production and purification of Flag-TWEAK, GpL-Flag-TNC-TWEAK and Fc-Flag-TWEAK have already been described elsewhere (7, 43) . NIK-, IB-and p-IB-specific antibodies were ordered from Cell Signaling (Frankfurt, Germany), PE conjugated anti-FcR1a (anti-CD64),
anti-FcR3a (anti-CD16) and unconjugated anti-FcR2a (anti-CD32A), antiFcR2b (anti-CD32B) from Santa Cruz Biotechnologies (Heidelberg, Germany) and anti-tubulin was from Dunn Labortechnik (Asbach, Germany). PE conjugated anti-TWEAK and anti-Fn14 antibodies were purchased from eBioscience (Frankfurt, Germany), anti-p100/p52 from Upstate (Schwalbach, Germany), anti-TRAF2 from BD Biosciences (Heidelberg, Germany), anti-cIAP1 from Enzo Life Sciences (Lörrach, Germany) and horseradish peroxidase-conjugated (HRP) secondary antibodies from Dako (Hamburg, Germany).
Determination of IL8 production -Cells (2 x 10 4 / well) were seeded in 96-well tissue culture plates and cultured over night. The following day, medium was exchanged to minimize background IL8 production of untreated cells. In the TWEAK inhibition experiments, cells were treated with the anti-Fn14 antibodies for 1 hour before cells were stimulated with TWEAK. In the coculture experiments with Fc receptor expressing transfectants, target cells were added to the transiently transfected Hek293 cells and 30 minutes later the mixture of cells was challenged with the different antibodies. 18 h post stimulation supernatants were collected and analyzed with respect to their IL8 content using a commercially available ELISA kit (BD Biosciences) according to the manufacturer´s instructions.
Western blotting analysis-For Western blot analysis of NIK accumulation and p100 processing whole cell lysates were prepared. Therefore cells were harvested into ice-cold phosphate buffered saline (PBS), centrifuged, then directly lysed in 4 x protein sample buffer (8 % SDS, 0.1 M DTT, 40 % glycerol, 0.2 M Tris (pH 6.8), 0.004 % bromphenol blue) supplemented with both complete protease inhibitor (Roche, Mannheim, Germany) and phosphatase inhibitor cocktails I and II (SigmaAldrich, Steinheim, Germany). Afterwards samples were sonificated (10 pulses). For analysis of depletion of TRAF2 and cIAP1 from the soluble compartment, cells (10 6 ) were lyzed for 20 min on ice in 100 µl Triton X100 buffer (30 mM Tris (pH 7.4), 10 % glycerol, 125 mM NaCl, 1 % Triton X100) supplemented with complete protease inhibitor (Roche) and phosphatase inhibitor cocktails I and II (SigmaAldrich). Lysates were cleared by centrifugation (14.000 rpm, 4 °C, 10 min) and mixed with 4 x protein sample buffer. Total cell lysates as well as Triton X100 lysates were boiled (95°C, 5 min), separated by SDS-PAGE and transferred to nitrocellulose membranes. After Flow cytometry -Cells were incubated for 20 min at 4°C with a PE-conjugated TWEAKspecific antibody (eBioscience, Frankfurt, Germany), anti CD16-PE, anti CD64-PE, anti CD32A/C and anti CD32B purchased from Santa Cruz Biotechnologies (Heidelberg, Germany) or an appropriate isotype control. In case of anti CD32A/C-and anti CD32B-antibody cells were again incubated 20 min at 4°C with an anti mouse-PE antibody. After three cycles of washing with PBS cells were analyzed using FACSCalibur (BD Biosciences, Heidelberg, Germany) according to standard procedures.
RESULTS
The anti-Fn14 mAb P4A8 efficiently blocks TWEAK-induced cellular reactions while the anti-Fn14 PDL192 barely interferes with TWEAK binding -We generate recombinant human IgG1 variants of the already described Fn14-specific antibodies PDL192 and P4A8 (BIIB036) (25) (26) (27) (28) (29) . Initially, we controlled Fn14 binding of the recombinant antibodies and confirmed that they recognize different epitopes. For this purposes, we used human, murine and cynomolgus Fn14 along with two mutants of human Fn14 (W42A and R56P) that do not interfere with ligand binding but either fail to interact with P4A8 (W42A) or with PDL192 (R65) (28, 29) . The various Fn14 variants were transiently expressed in Hek293 cells which have only low amounts of endogenous Fn14 and antibody binding was evaluated by FACS (Fig.  1A) . As expected based on the available literature (25) (26) (27) (28) (29) , both antibodies yielded effective staining of human and cynomolgus Fn14 but reacted differently with murine Fn14 and the two mutants of human Fn14. PDL192 failed to interact with murine Fn14 and the R56P variant but significantly bound to the W42A mutant of human Fn14. In contrast, P4A8 did not interact with the latter but recognized murine Fn14 as well as R56P variant (Fig. 1A) . In sum, this confirmed that PDL192 and P4A8 recognize two different epitopes.
Next, we analyzed the capability of the two anti-Fn14 antibodies to inhibit distinct TWEAKinduced cellular effects known to be mediated by Fn14. The Fn14-mediated induction of proinflammatory cytokines and chemokines by TWEAK has been demonstrated in a variety of cell lines. Pretreatment of HT29 and WiDr cells with PDL192 and P4A8 resulted in case of the latter in strong inhibition of TWEAK-induced IL8 production while PDL192 showed only weak to moderate inhibition at high concentrations (Fig. 1B) . The TWEAK-Fn14 system has also been recognized in some cell lines, for example SKOV3 and Kym-1, as a cell death inducer. In accordance with the inhibitory effect of P4A8 on TWEAK-induced IL8 production, we also observed complete blockade of TWEAK-induced cell death in SKOV3 and Kym-1 cells. PDL192 again showed at best a minor inhibitory effect and only at the highest concentrations (Fig. 1C) . Likewise, the capability of TWEAK to enhance TNFR1-induced cell death in per se TWEAK-resistant cell lines were blocked by P4A8 but not by PDL192 (Fig. 1D ). Last but not least, P4A8 also rescued the inhibitory effect of TWEAK on BMP2-induced production of alkaline phosphatase in the murine C2C12 model of osteoblastogenesis while PDL192, which does not recognize murine Fn14, showed no effect (Fig. 1E) . To evaluate the disparate inhibitory effect of the two anti-Fn14 antibodies on the interaction of TWEAK with murine and human Fn14 directly, we performed competition binding experiments with GpL-TNC-Flag-TWEAK and C2C12 and HT29 cells (Fig. 1F) . While P4A8 inhibited binding of the GpL-TWEAK fusion protein efficiently, there was practically no competition between the TWEAK variant and PDL192 for Fn14 binding (Fig. 1F) .
In all functional assays described above, Fn14 was activated by help of Fc-Flag-TWEAK a highly active recombinant hexameric soluble variant of TWEAK eliciting the same cellular responses as membrane-bound TWEAK (7). Next, we tested whether P4A8 has also the capability to block the interaction of Fn14 with membrane-bound TWEAK. We thus evaluated the inhibitory effect of PDL192 and P4A8 in a coculture model where Hek293 cells transiently transfected with a non-cleavable mutant of membrane TWEAK ( Fig. 2A) were used to stimulate IL8 production in HT1080 cells. In this type of assay, P4A8 showed again a strong inhibitory effect already at comparable low concentrations while PDL192 again elicited at best a very moderate effect at the maximal used concentration of 10 µg/ml (Fig. 2B) .
Fn14-specific antibodies elicit strong agonistic activity upon oligomerization with protein G -It has been reported for other antibodies recognizing the TNF receptor superfamily members CD95 and TRAILR2 that oligomerization can strongly enhance their agonistic activity (30) (31) (32) (33) . We therefore wondered whether PDL192 and P4A8 possess a latently present agonistic activity that can be unleashed by oligomerization. Thus, we oligomerized the two anti-Fn14 mAbs with protein G and reinvestigated their effects on Fn14-mediated induction of IL8 and cell death (Fig. 3A,B) . It turned out that protein Gmediated oligomerization converted both antiFn14 mAbs in highly active agonists inducing cell death in SKOV-3 cells at low concentrations and triggering a strong IL8 response in WiDr and HT29 cells (Fig. 3A,B) . In accordance with the crucial role of classical NFB signaling for induction of IL8 gene transcription, we also observed nuclear translocation of the p65/RelA NFB subunit, a hallmark of activation of the classical NFB pathway (34) , only with the oligomerized anti-Fn14s (Fig. 3C) . Antibody concentrations up to 10 µg/ml failed to elicit significant IL8 production or cell death induction in the absence of protein G. Several other Fn14-specifc mAbs that we have not investigated here in detail also elicited agonistic activity upon protein G-oligomerization (data not shown). This suggests that the sole aggregation of Fn14 molecules commonly results in receptor activation without special requirements with respect to spatial organization and receptor topology.
The (Fig. 4A,B) were cocultivated with WiDr or HT29 cells which produce high amounts of IL8 upon Fn14 stimulation and then the cocultures were supplemented with PDL192 and P4A8. Interaction with all four types of Fc receptor enabled the two anti-Fn14 mAbs to trigger a strong IL8 response with ED50-values below concentrations of 100 ng/ml while there was no IL8 induction with a corresponding isotype control antibody (Fig. 4A,B) . Thus, binding of anti-Fn14 IgG1 to Fc receptors is fully sufficient to convert these molecules in highly active agonists for Fn14 even in case of P4A8 which is otherwise a potent antagonist.
Anti-Fn14 mAbs act as agonists of the alternative NFB pathway without oligomerization or FcR binding -Two pathways that are relevant for the majority of Fn14-mediated cellular effects are the classical and the alternative NFB pathway. These two pathways are activated with different efficacy by membrane-bound TWEAK and soluble TWEAK trimers (7) . While the alternative NFB pathway is strongly stimulated by both forms of TWEAK, membrane-bound TWEAK is superior to soluble TWEAK in activation of the classical NFB pathway (7) . In line with this, artificial attachment of trimeric TWEAK to cells lowers the ED 50 -value of IL8 induction several 100fold but has no effect on the dose response dependency of p100 processing, the biochemical hallmark of alternative NFB signaling (7). Noteworthy, hexameric soluble TWEAK, as used in the experiments shown in figure 1 , and oligomerized TWEAK trimers are also highly superior to soluble TWEAK trimers with respect to classical NFB signaling but all three TWEAK species are comparable active with respect to p100 processing (7). Complexes of TRAF2 and cIAP1/2 inhibit the alternative NFB pathway upstream of NIK accumulation and p100 processing and also prevent TNFR1-induced apoptosis upon recruitment to this receptor (35, 36) . In accordance, it has been found that Fn14-induced enhancement of TNFR1-induced cell death, like alternative NFB signaling, is efficiently triggered by all forms of TWEAK (6) . In view of the results shown above, it therefore appears that oligomerized and Fc receptor-bound anti-Fn14 mAbs resemble membrane-bound TWEAK and potently trigger the complete set of Fn14-associated signaling pathways. P4A8 furthermore act otherwise as an antagonist of soluble and membrane-bound TWEAK (Fig. 1) . For example, it blocked Fn14-mediated enhancement of TNFR1-induced cell death upon stimulation with the membrane-TWEAK mimicking Fc-TWEAK construct (Fig. 1D) but also when trimeric Flag-TWEAK was used for Fn14 stimulation (Fig. 5A) . Biochemical and microscopical analysis of alternative NFB signaling revealed, however, a more complex situation. Although P4A8 inhibited enhancement of TNF-induced cell death by trimeric soluble TWEAK efficiently, it nevertheless significantly triggered p100 processing and nuclear translocation of p52 at low to moderate concentrations (> 1 µg/ml; Fig. 5B,D) . In view of the fact that soluble TWEAK trimers stimulate both, p100 processing and enhancement of TNF-induced apoptosis, by depletion of cytosolic TRAF2-cIAP1/2 complexes this observation is surprising (Fig.  5B-D) . Moreover, PDL192 also triggered the alternative NFB pathway efficiently without showing enhancement of TNFR1-induced cell death ( Fig. 5B-D) . Noteworthy, in accordance with the capability of the oliogmerized antiFn14s to stimulate the classical NFB pathway there was an increase in the total amount of p100 and p52 in the cells stimulated with the oliogmerized antibodies (Fig. 5B) . A possible explanation of this at the first glance contradictory situation appears when NIK accumulation was analyzed. Stimulation of p100 processing by PDL192 and P4A8 was almost as strong as by Flag-TWEAK. The latter, however, triggered a much higher NIK accumulation (Fig.  5B) . As NIK accumulation is the direct consequence of depletion of TRAF2-cIAP1/2 complexes this suggested that the anti-Fn14 antibodies are far less active in TRAF2-cIAP1/2 depletion than Flag-TWEAK trimers what would correspond well to the fact that the antiFn14 antibodies, in contrast to Flag-TWEAK, failed to enhance TNF-induced cell death. We therefore analyzed the impact of the various Fn14 targeting reagents on TRAF2 and cIAP1. We and others previously showed that TRAF2 translocates to a Fn14/membrane-associated Triton X100-insoluble compartment in response to TWEAK stimulation (6, 37) . In confirmation of these earlier results, we observed that both TWEAK variants (soluble TWEAK and the membrane TWEAK-mimicking Fc-TWEAK) as well as the oligomerized anti-Fn14s triggered significant depletion of TRAF2 and cIAP1 from the Triton X100 soluble fraction (Fig. 5E ).
However, there was no significant reduction in TRAF2 and cIAP1 levels in the Triton X100 soluble fraction of cells challenged with nonoligomerized P4A8 and PDL192 despite robust p100 processing (Fig. 5E) . The fact that minor depletion of TRAF2-cIAP1/2 and poor NIK accumulation are already sufficient to trigger considerable p100 processing without sensitizing for TNFR1-induced cell death might thus most likely reflect different thresholds of TRAF2-cIAP1/2 for these two responses. Indeed, this idea corresponds well to the molecular mode of action of the two responses. In case of p100 processing the moderate effect on NIK expression is potentiated as it act catalytically and can thus activate a huge number of IKK1 molecules which in turn again can trigger the processing of multiple p100 molecules. In contrast, in context of the TRAF2-cIAP1/2 complex mediated crosstalk of Fn14 and TNFR1 there are no such amplification mechanisms and the Fn14-induced depletion of the cytosolic TRAF2-cIAP1/2 complexes must thus be strong enough to push their concentration below a critical limit.
DISCUSSION
We investigated here in detail the effects of the two Fn14-specific antibodies PDL192 and P4A8 on Fn14 activity. Both antibodies showed no agonistic activity with respect to production of IL8, cell death induction and enhancement of TNFR1-induced cell death up to concentrations of 10 µg/ml. While PDL192 poorly affected ligand binding and this also only at high concentrations, P4A8 inhibited TWEAK binding and thus blocked the aforementioned Fn14-mediated responses (Fig. 1,2) . Both anti-Fn14 mAbs, however, triggered the aforementioned Fn14-mediated effects upon oligomerization with protein G or binding to Fc-receptors (Fig.  3,4) . Naturally, Fn14 is activated by membrane TWEAK or a soluble form derived thereof by proteolytic processing. Notably, binding of the two forms of TWEAK trigger qualitatively distinct states of Fn14 activity. Soluble TWEAK stimulates the alternative NFB pathway and enhances TNFR1-induced cell death but only weakly triggers signaling via the classical NFB pathway. In contrast, membrane TWEAK is a potent inducer of all of these pathways (6, 7) . Thus, the fact that oligomerized or FcR-bound anti-Fn14 mAbs are quite effective in the stimulation of all Fn14 responses investigated, including activation of the classical NFB pathway, indicates that they mimic the activity of membrane TWEAK. Without oligomerization or FcR binding, however, the effects of PDL192 and P4A8 on Fn14 activity are quite complex. On the one hand, we observed that both anti-Fn14 antibodies efficiently trigger p100 processing and nuclear translocation of p52, hallmarks of the alternative NFB pathway (Fig. 5B,D) . Thus, in this respect PDL192 and P4A8 resemble soluble TWEAK. On the other side, in contrast to soluble TWEAK both antiFn14 mAbs showed no effect on TNFR1-induced cell death and in case of P4A8 this response of soluble TWEAK was actually blocked (Figs. 1D and 5A ). In sum, this means that binding of antibodies in the absence of oligomerization or FcR-binding induces in a state of Fn14 activity distinct from those triggered by soluble and membrane TWEAK. In case of blocking antibodies such as PDL192 this has the quite unusual and paradoxical effect that an antibody concomitantly displays agonistic and antagonistic activities.
The unexpected and unprecedented pathwayspecific agonistic activity of an otherwise antagonistic antibody that we observed for P4A8 as well as the "agonism constituting" effect of FcR-binding are not only of academic interest but of considerable relevance with respect to potential clinical applications of Fn14-specific antibodies. The TWEAK/Fn14 system is currently under clinical and preclinical investigation as a therapeutic target in tumor therapy and autoimmune diseases but also in various injuries related to traumatic tissue damage (http://clinicaltrials.gov, (1,38) ). In case of tumor therapy with anti-Fn14 mAbs, FcR binding is typically desirable to elicit an ADCCrelated antitumoral effect. Now, our results suggest that in case of ADCC-resistance this might lead to Fn14 activation and stimulation of potentially protumoral Fn14-induced effects even then when the antibody used for treatment act as an antagonist in in vitro assays. This also applies to most of the remaining potential applications of anti-Fn14 mAbs where inhibition of TWEAK/Fn14-induced signaling is aimed. The introduction of mutations or modifications in the Fc part of Fn14 antibodies that prevent their binding to Fc receptors could deliver here a solution but only as long as the anticipated therapeutic effect does not require inhibition of Fn14-induced activation of the alternative NFB pathway. In situations, however, where Fn14-driven activation of the alternative NFB pathway contributes to the disease this would be no solution as the alternative NFB-pathway specific agonistic activity of otherwise antagonistic Fn14 antibodies remains unaffected and could actually exacerbate the disease. In this case only TWEAK-neutralizing reagents and monomeric Fn14 antagonists would be useful.
TWEAK is a trimer that interacts with three Fn14 molecules while the IgG1 antibodies used in this study have only two Fn14 binding sides. This suggests that the alternative NFB pathway is unique among the Fn14-associated signaling pathways as it is already highly responsive to Fn14 dimerization allowing antibodies to trigger an unusual response pattern distinct from that of the naturally occurring Fn14 ligands. Based on the established trimeric structure of TRAF2 (39, 40) and what is known about the role of TRAF2 and cIAPs in NFB signaling (34, 36) , we propose the following model (Fig. 6 ) of antibody-, soluble TWEAK and membrane TWEAK-induced Fn14 activation:
In non-stimulated cells Fn14 predominately occurs as monomers that do not interact with TRAF2-cIAP complexes or only undergo shortlived instable interactions with one of the three TRAF2 protomers contained in a TRAF2-cIAP complex. In any case there is no relevant activation of Fn14-related signaling pathways (Fig. 6, ground state) . If bivalent Fn14-specific antibodies are applied, Fn14 become trapped in complexes containing two adjacent Fn14 molecules (Fn14-Fn14 2 ). Now, two Fn14 molecules of such a complex concomitantly interact with two of the three protomers of a TRAF2 trimer resulting in enhanced but still transient and submaximal interaction between Fn14 molecules and TRAF2-cIAP complexes. The Fn14 interaction with TRAF2-cIAP complexes is now strong enough to result in a minor depletion of cytosolic TRAF2-cIAP complexes or the displacement of the latter from NIK degradation-triggering TRAF2-cIAP-TRAF3-NIK complexes. The resulting very weak accumulation of NIK, however, is relevant enough to trigger p100 processing because this involves two catalytic amplification steps, NIKmediated phosphorylation and activation of IKK1 and phosphorylation of p100 by the latter resulting in p100 processing (Fig. 6 , activity state I). TRAF2-cIAP complexes also inhibit caspase-8 activation in context of TNFR1 signaling and thus protects against TNF-induced apoptosis (41) . Here, the TRAF2-cIAP complexes act in a stoichiometric manner without amplificatory mechanisms. Thus, the minor reduction in the availability of TRAF2-cIAP complexes related to the weak depletion caused by antibody stimulation of anti-Fn14 is too weak to get apparent. With respect to the activation of the classical NFB pathway transinteraction of two IAPs seems to be necessary. As a TRAF2 trimer interacts with only a single cIAP molecule (42) , this cannot occur in the anti-Fn14-induced complexes of two Fn14 molecules with a single TRAF2 trimer.
In case of soluble TWEAK, a ligand trimer interacts with three Fn14 molecules (TWEAKFn14 3 ) resulting in a complex that can undergo concomitant interaction all protomers of a TRAF2 trimer resulting in stronger durable recruitment of TRAF2-cIAP complexes than in case of the anti-Fn14 induced receptor dimers. As a consequence there is significant depletion of cytosolic TRAF2-cIAP complexes. Now, the latter is strong enough to lead to enhancement of TNF-induced apoptosis and also to much stronger NIK accumulation (Fig. 6 , activity state II). Due to the two amplificatory catalytic steps connecting NIK accumulation and p100 processing, however, the alternative pathway was already maximally triggered by low NIK levels so that the further increase in NIK accumulation has no chance to translate in a corresponding enhanced p100 processing activity. There is still no or only weak classical NFB signaling as there is still no transinteraction of two TRAF2-IAPs complexes due to the lack of secondary interaction of two TWEAK-Fn14 3 complexes.
In case of stimulation of membrane TWEAK, oligomerized soluble TWEAK trimers or hexameric Fc-TWEAK, the TWEAK-Fn14 3 complexes become oligomerized resulting in close neighborhood of two or more TRAF2-cIAP complexes and trans-activation of two IAPs and thus additional activation of the classical NFB pathway (Fig. 6, activity state  III) . Likewise, protein G oligomerization and FcR-binding lead to supramolecular clustering of several Fn14-Fn14 2 complexes resulting in tighter binding of TRAF2-cIAP complexes and again in transactivation of the IAP component of these complexes and stimulation of the classical NFB pathway (Fig. 6, activity (C) HT29 cells were treated for 6 h in triplicates with 1 µg/ml of PDL192 and P4A8 with and without protein G oligomerization and with Flag-TWEAK and Fc-Flag-TWEAK (200 ng/ml). Cells were then stimulated with TNF and CHX (2.5µg/ml) to trigger TNFR1-induced cell death. After overnight incubation cellular viability was again determined by crystal violet staining. The dose response data for TNF alone was indicated as a dotted line in all panels for better comparison. (D) HT29 cells were grown on glass coverslips and were stimulated the next day with the two anti-Fn14 antibodies (1 µg/ml) in the presence and absence of protein G (1 µg/ml)or with Flag-TWEAK (200 ng/ml) or Fc-Flag-TWEAK (200 ng/ml) over night. Cells were then stained with an antibody recognizing p100/p52. Shown are representative images (left panel) and the ratio of nuclear to cytoplasmic fluorescence intensity (right panel). To calculate the ratio of nuclear to cytoplasmic fluorescence intensity, 30 cells of each group were measured. (E) HT29 and WiDr cells were challenged with Flag-TWEAK (200 ng/ml), Fc-Flag-TWEAK (200 ng/ml) and the anti-Fn14 antibodies (2 µg/ml) with and without oligomerization by protein G (0.5 µg/ml) overnight. Triton X100 lysates were prepared and analyzed by Western blotting with respect to the indicated proteins. 
